XPHYF News and Press, XPhyto Therapeutics Corp From 01/10/22

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced two key appointments to continue its focus on research, development an...

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / January 10, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce two key appointments to continue its focus on research, development and commercialization of its biosensor ...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today provided an update on the development of its fast-dissolving CBD oral strips. Wi...

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 15, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has completed its acquisition of 3a-diagnostics GmbH (“3a”), first annou...

The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technology The acquisition of 3a, a German-based rapid point-of-care diagnostics firm adds IP and a deeply experienced scientific expertise to XPhyto ...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / December 3, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (the " Company " or " XPhyto ") announces that it has issued an aggregate...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / November 26, 2021 / XPhyto Therapeutics Corp. (" XPhyto " or the " Company ") (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that further to its news release da...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, has named a new chief financial officer: Joseph Meagher. A chartered professional accountant (“CPA, CA”) and a chartered director, Meaghe...

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / November 19, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Joseph Meagher as Chief Financial Officer of the Company. Mr. Meagher is a Charter...